Preferences of German melanoma patients for interferon (IFN) α-2b toxicities (the DeCOG “GERMELATOX survey”) versus melanoma recurrence to quantify patients’ relative values for adjuvant therapy

Currently interferon alfa-2b (IFNα-2b) is an approved adjuvant drug for high-risk melanoma patients that leads to an improvement in disease-free survival (DFS). However, it is unclear whether it also impacts overall survival. Widespread use of adjuvant high-dose IFNα has been tempered by its signifi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaehler, Katharina C., Blome, Christine, Forschner, Andrea, Gutzmer, Ralf, Haalck, Thomas, Heinzerling, Lucie, Kornek, Thomas, Livingstone, Elisabeth, Loquai, Carmen, Maul, Lara Valeska, Lang, Berenice M., Schadendorf, Dirk, Stade, Barbara, Terheyden, Patrick, Utikal, Jochen, Wagner, Tobias, Hauschild, Axel, Garbe, Claus, Augustin, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120927/
https://www.ncbi.nlm.nih.gov/pubmed/27861370
http://dx.doi.org/10.1097/MD.0000000000005375

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120927/
https://www.ncbi.nlm.nih.gov/pubmed/27861370
http://dx.doi.org/10.1097/MD.0000000000005375

Ejemplares similares